Genocea commences Phase 1/2a study of GEN-003
06:30 EDT 16 Aug 2012 | Pharmaceutical Business Review
Genocea Biosciences has initiated Phase 1/2a study with GEN-003, an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-s..
Original Article: Genocea commences Phase 1/2a study of GEN-003
More From BioPortfolio on "Genocea commences Phase 1/2a study of GEN-003"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
